The stock price of Essa Pharma Inc (NASDAQ: EPIX) has dropped by -10.64 compared to previous close of 6.77. Despite this, the company has seen a fall of -14.31% in its stock price over the last five trading days. prnewswire.com reported 2024-09-13 that Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA
Is It Worth Investing in Essa Pharma Inc (NASDAQ: EPIX) Right Now?
Additionally, the 36-month beta value for EPIX is 1.82. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EPIX is 43.38M and currently, short sellers hold a 2.38% ratio of that float. The average trading volume of EPIX on September 19, 2024 was 52.53K shares.
EPIX’s Market Performance
The stock of Essa Pharma Inc (EPIX) has seen a -14.31% decrease in the past week, with a 13.94% rise in the past month, and a 29.83% gain in the past quarter. The volatility ratio for the week is 14.28%, and the volatility levels for the past 30 days are at 9.84% for EPIX. The simple moving average for the past 20 days is 2.46% for EPIX’s stock, with a -10.63% simple moving average for the past 200 days.
Analysts’ Opinion of EPIX
Many brokerage firms have already submitted their reports for EPIX stocks, with Oppenheimer repeating the rating for EPIX by listing it as a “Outperform.” The predicted price for EPIX in the upcoming period, according to Oppenheimer is $17 based on the research report published on June 26, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see EPIX reach a price target of $50. The rating they have provided for EPIX stocks is “Overweight” according to the report published on March 04th, 2021.
H.C. Wainwright gave a rating of “Buy” to EPIX, setting the target price at $17 in the report published on January 11th of the previous year.
EPIX Trading at 11.95% from the 50-Day Moving Average
After a stumble in the market that brought EPIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.16% of loss for the given period.
Volatility was left at 9.84%, however, over the last 30 days, the volatility rate increased by 14.28%, as shares surge +13.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.73% upper at present.
During the last 5 trading sessions, EPIX fell by -14.31%, which changed the moving average for the period of 200-days by +13.72% in comparison to the 20-day moving average, which settled at $5.94. In addition, Essa Pharma Inc saw -8.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EPIX starting from Virsik Peter, who sale 694 shares at the price of $6.00 back on Sep 09 ’24. After this action, Virsik Peter now owns 8,470 shares of Essa Pharma Inc, valued at $4,164 using the latest closing price.
Virsik Peter, the Chief Operating Officer of Essa Pharma Inc, sale 2,082 shares at $6.03 during a trade that took place back on Sep 03 ’24, which means that Virsik Peter is holding 9,164 shares at $12,554 based on the most recent closing price.
Stock Fundamentals for EPIX
The total capital return value is set at -0.23. Equity return is now at value -19.83, with -19.33 for asset returns.
Based on Essa Pharma Inc (EPIX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -69.3. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -26748.78.
Currently, EBITDA for the company is -26.46 million with net debt to EBITDA at 2.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 36.95.
Conclusion
In conclusion, Essa Pharma Inc (EPIX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
